Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 9957 | 1040 | 28.2 | 67% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | CYFRA 21 1 | Author keyword | 222 | 74% | 16% | 165 |
| 2 | CYTOKERATIN 19 FRAGMENTS | Author keyword | 34 | 93% | 1% | 13 |
| 3 | PROGRP | Author keyword | 22 | 66% | 2% | 21 |
| 4 | CYFRA21 1 | Author keyword | 18 | 61% | 2% | 19 |
| 5 | CYTOKERATIN 19 FRAGMENT | Author keyword | 13 | 67% | 1% | 12 |
| 6 | CYFRA 211 | Author keyword | 10 | 61% | 1% | 11 |
| 7 | PRO GASTRIN RELEASING PEPTIDE | Author keyword | 10 | 57% | 1% | 12 |
| 8 | NSE | Author keyword | 9 | 18% | 4% | 44 |
| 9 | CYFRA | Author keyword | 8 | 70% | 1% | 7 |
| 10 | CYTOKERATIN 19 FRAGMENT ANTIGEN 21 1 | Author keyword | 8 | 100% | 0% | 5 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | CYFRA 21 1 | 222 | 74% | 16% | 165 | Search CYFRA+21+1 | Search CYFRA+21+1 |
| 2 | CYTOKERATIN 19 FRAGMENTS | 34 | 93% | 1% | 13 | Search CYTOKERATIN+19+FRAGMENTS | Search CYTOKERATIN+19+FRAGMENTS |
| 3 | PROGRP | 22 | 66% | 2% | 21 | Search PROGRP | Search PROGRP |
| 4 | CYFRA21 1 | 18 | 61% | 2% | 19 | Search CYFRA21+1 | Search CYFRA21+1 |
| 5 | CYTOKERATIN 19 FRAGMENT | 13 | 67% | 1% | 12 | Search CYTOKERATIN+19+FRAGMENT | Search CYTOKERATIN+19+FRAGMENT |
| 6 | CYFRA 211 | 10 | 61% | 1% | 11 | Search CYFRA+211 | Search CYFRA+211 |
| 7 | PRO GASTRIN RELEASING PEPTIDE | 10 | 57% | 1% | 12 | Search PRO+GASTRIN+RELEASING+PEPTIDE | Search PRO+GASTRIN+RELEASING+PEPTIDE |
| 8 | NSE | 9 | 18% | 4% | 44 | Search NSE | Search NSE |
| 9 | CYFRA | 8 | 70% | 1% | 7 | Search CYFRA | Search CYFRA |
| 10 | CYTOKERATIN 19 FRAGMENT ANTIGEN 21 1 | 8 | 100% | 0% | 5 | Search CYTOKERATIN+19+FRAGMENT+ANTIGEN+21+1 | Search CYTOKERATIN+19+FRAGMENT+ANTIGEN+21+1 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CYFRA 21 1 | 118 | 52% | 15% | 159 |
| 2 | NSE | 43 | 48% | 6% | 66 |
| 3 | DISEASE EXTENT | 23 | 64% | 2% | 23 |
| 4 | TISSUE POLYPEPTIDE ANTIGEN | 21 | 31% | 5% | 56 |
| 5 | CEA | 18 | 12% | 13% | 138 |
| 6 | CYTOKERATIN 19 FRAGMENTS | 14 | 57% | 2% | 16 |
| 7 | TUMOR MARKER | 11 | 10% | 10% | 100 |
| 8 | PEPTIDE PROGRP | 8 | 70% | 1% | 7 |
| 9 | SCC | 7 | 15% | 4% | 43 |
| 10 | MULTIPLE BIOMARKER ASSAY | 7 | 64% | 1% | 7 |
Journals |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | JOURNAL OF TUMOR MARKER ONCOLOGY | 2 | 11% | 2% | 18 |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Carcinoembryonic antigen (CEA) as tumor marker in lung cancer | 2012 | 48 | 32 | 72% |
| Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: Analysis of 116 cases and review of the literature | 2005 | 65 | 21 | 90% |
| Tumor markers in detection of lung cancer | 2006 | 71 | 125 | 71% |
| Biomarkers for the lung cancer diagnosis and their advances in proteomics | 2008 | 68 | 99 | 37% |
| Research Progress in Applying Proteomics Technology to Explore Early Diagnosis Biomarkers of Breast Cancer, Lung Cancer and Ovarian Cancer | 2014 | 3 | 96 | 33% |
| ProGRP: a new biomarker for small cell lung cancer | 2004 | 62 | 36 | 64% |
| Serum markers in small cell lung cancer: Opportunities for improvement | 2013 | 13 | 236 | 22% |
| Clinical utility of cytokeratins as tumor markers | 2004 | 146 | 84 | 23% |
| CLINICAL TUMOR-MARKERS IN LUNG-CANCER | 1995 | 62 | 77 | 51% |
| Clinical value of using serological cytokeratins as therapeutic markers in thoracic malignancies | 2007 | 2 | 50 | 70% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CUNEO LUNG CANC STUDY GRP | 3 | 45% | 0.5% | 5 |
| 2 | ONCOBIOL UNIT | 3 | 60% | 0.3% | 3 |
| 3 | BEIJNG CHEST HOSP | 1 | 100% | 0.2% | 2 |
| 4 | IMMUNORADIOASSAY | 1 | 50% | 0.2% | 2 |
| 5 | PRIMARY REFERENCE CLIN PLICAT LUNG TUMOUR M | 1 | 100% | 0.2% | 2 |
| 6 | POLIKLIN ARBEITS SOZIALMED | 1 | 13% | 0.9% | 9 |
| 7 | IMMUNOL TUMOR DIAG | 1 | 16% | 0.7% | 7 |
| 8 | RADIO ANAL | 1 | 33% | 0.2% | 2 |
| 9 | BAYLOR SCOTT WHITE DIGEST DIS | 1 | 50% | 0.1% | 1 |
| 10 | CLIN PULM DIS JORDANOVAC | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000284809 | SQUAMOUS CELL CARCINOMA ANTIGEN//SCC ANTIGEN//SERPINB3 |
| 2 | 0.0000168915 | SMALL CELL LUNG CANCER CELL LINE//SMALL CELL LUNG CANCER CELL LINES//DRUG SCREENING ASSAY |
| 3 | 0.0000152027 | CA 15 3//CA 153//TISSUE POLYPEPTIDE SPECIFIC ANTIGEN |
| 4 | 0.0000112081 | ENOLASE//ALPHA ENOLASE//PLASMINOGEN BINDING |
| 5 | 0.0000098450 | DITHIONITROBENZOATE//IGG BLOOD//YOSHIDA HEPATOMA |
| 6 | 0.0000085211 | M65//M30//M65 ELISA |
| 7 | 0.0000083438 | CA 19 9//CA19 9//SPAN 1 |
| 8 | 0.0000069315 | LARGE CELL NEUROENDOCRINE CARCINOMA//TYPICAL CARCINOID//ATYPICAL CARCINOID |
| 9 | 0.0000059140 | TUBERCULOUS PLEURISY//TRANSUDATES//PLEURAL EFFUSION |
| 10 | 0.0000058477 | CA 125//HE4//HUMAN EPIDIDYMIS PROTEIN 4 |